Covid-19 roundup: Zy­dus Cadi­la sub­mits 3-dose vac­cine for reg­u­la­to­ry ap­proval; US do­nates Mod­er­na jabs to Pak­istan dur­ing short­age

In­dia’s sec­ond home-grown vac­cine could be ap­proved by reg­u­la­tors soon as Zy­dus Cadi­la an­nounced Thurs­day it has ap­plied for emer­gency use ap­proval with reg­u­la­tors in that na­tion.

The jab has demon­strat­ed ef­fi­ca­cy of 66.6%, and the com­pa­ny says stud­ies have shown it is safe for chil­dren be­tween the ages of 12 and 18 years old. The vac­cine’s piv­otal study was car­ried out in more than 50 clin­i­cal sites across In­dia dur­ing the peak of the coun­try’s sec­ond wave, which Cadi­la says reaf­firms the ef­fi­ca­cy against the Delta vari­ant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER